10-K: BioVie Faces Going Concern Amid Legal Woes, Trial Setbacks

BioVie Inc. reports a reduced net loss but faces substantial doubt about its ability to continue as a going concern, grappling with ongoing securities litigation and past clinical trial integrity issues.

Summary

• BioVie Inc. is a clinical-stage biopharmaceutical company developing drug therapies for neurological and neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease (ascites).
• The company reported a net loss of approximately $17.5 million for the fiscal year ended June 30, 2025, a decrease from $32.1 million in the prior year.
• Research and development expenses decreased by $13.8 million to $9.3 million in FY2025, primarily due to the completion of prior clinical studies.
• Selling, general and administrative expenses were comparable at approximately $8.6 million in FY2025.
• Cash and cash equivalents stood at approximately $17.5 million, with working capital of $18.4 million as of June 30, 2025.
• The accumulated deficit reached approximately $352.1 million as of June 30, 2025.
• The company received a $13.1 million clinical trial grant from the U.S. Department of Defense (DOD) in April 2024 for its Long COVID program.
• A Phase 2b study of bezisterim for new onset Parkinson's disease commenced in April 2025, and a Phase 2 ADDRESS-LC study for Long COVID commenced in May 2025.
• The Phase 3 Alzheimer's disease trial for bezisterim (NCT04669028) experienced significant protocol deviations and cGCP violations at 15 study sites, leading to patient exclusions and the trial being underpowered for primary endpoints.
• An observed descriptive change in the Per-Protocol population of the AD trial suggested a slowing of cognitive decline and an advantage in age deceleration.
• The company is finalizing the protocol design for a Phase 3 study of BIV201 for cirrhosis and ascites, targeting a broader patient population.
• BioVie is currently subject to securities class action litigation and shareholder derivative lawsuits related to alleged misrepresentations concerning the AD Phase 3 study, with a motion to dismiss denied in March 2025.
• The company completed registered direct offerings in September and October 2024, raising approximately $3.0 million and $15.9 million in gross proceeds, respectively.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, severe integrity issues and underpowering of the pivotal Alzheimer's trial, and ongoing, costly securities litigation. While there are positives like a significant DOD grant and new trials commencing, these are overshadowed by the fundamental financial viability and legal challenges, indicating a high-risk, precarious situation.

Positives

• Net loss decreased significantly to $17.5 million in FY2025 from $32.1 million in FY2024, primarily due to reduced R&D expenses.
• Awarded a substantial $13.1 million clinical trial grant from the U.S. Department of Defense for the Long COVID program.
• FDA and U.S. Army Medical Research and Development Command approved the plan and IND for bezisterim in Long COVID, with the Phase 2 ADDRESS-LC study commencing in May 2025.
• FDA permitted the company to proceed with a new Phase 2b study of bezisterim for new onset Parkinson's disease, which commenced in April 2025.
• BIV201 (continuous infusion terlipressin) has been granted FDA Fast Track designation and Orphan Drug Status for ascites and hepatorenal syndrome.
• Patents for BIV201's novel liquid formulation have been granted in the U.S., China, Japan, Chile, and India, offering potential product differentiation with room temperature stability.
• The Phase 2 PD study (NCT05083260) met both primary (safety and drug-drug interaction) and secondary (promotoric activity and levodopa enhancement) objectives, showing significant improvements in morning on symptoms and motor control.
• In the Per-Protocol population of the AD trial, an observed descriptive change suggested a slowing of cognitive decline and an advantage in age deceleration, despite the trial being underpowered.

Negatives

• The company has not generated any revenues to date and does not expect to in the foreseeable future, raising substantial doubt about its ability to continue as a going concern.
• The Phase 3 Alzheimer's disease trial (NCT04669028) was significantly compromised by protocol deviations and cGCP violations at 15 study sites, leading to patient exclusions and the trial being underpowered for its primary endpoints.
• The company is currently subject to securities class action litigation and two shareholder derivative lawsuits alleging material misrepresentations related to the AD Phase 3 study, which will incur significant legal expenses and management time.
• The company's insurance coverage for the lawsuits is subject to a $2 million deductible, meaning the company is responsible for the first $2 million in costs.
• The reverse stock split effected on July 7, 2025, has caused and could further cause the stock price to decline relative to its value before the split and decrease liquidity.
• The company has a substantial accumulated deficit of approximately $352.1 million as of June 30, 2025.
• The company has limited experience in drug development and no manufacturing experience, relying heavily on third parties, which introduces significant risks.

Risks

• Reliance on third-party contractors (CROs, clinical trial sites, manufacturers) to conduct clinical trials and comply with regulatory requirements, with potential for delays or failure to obtain regulatory approval.
• High uncertainty in successful biopharmaceutical development, with product candidates potentially failing at any stage due to ineffectiveness, harmful side effects, or regulatory hurdles.
• Concentration of cash assets in a single financial institution, exposing the company to liquidity risks in case of bank failures.
• Ongoing securities class action and derivative litigation, which could result in substantial damages, fines, and diversion of management resources.
• Inability to generate revenues or achieve profitability, potentially leading to cessation of operations.
• Limited operating history as a development-stage company, making business evaluation difficult for investors.
• Potential for generic versions of approved products or insufficient exclusivity periods, adversely affecting sales.
• Failure to obtain or maintain Orphan Drug exclusivity for BIV201, reducing competitive protection.
• Need to raise substantial additional capital in the future, with no assurance of obtaining sufficient financing on acceptable terms, which could lead to delays or termination of programs.
• Lack of internal manufacturing experience and reliance on Contract Manufacturing Organizations (CMOs), with risks of non-compliance with cGMP regulations and supply shortages.
• Absence of internal sales and marketing personnel, requiring reliance on third parties or significant future hiring and capital investment.
• Compliance with significant and complex government regulations, which may delay or prevent commercialization.
• Loss or unavailability of key management personnel, putting the company at a competitive disadvantage.
• Inability to attract and retain highly skilled personnel in a competitive industry.
• Competition from larger, better-resourced biotechnology and biopharmaceutical companies.
• Conflicts of interest among officers, directors, and stockholders due to other business activities.
• Inability to obtain or protect intellectual property rights, including patents, which could allow competitors to develop similar products.
• Potential for intellectual property litigation, which is expensive, time-consuming, and could result in unfavorable outcomes.
• Volatility of the company's stock price and potential for future dilution from equity offerings or warrant/option exercises.
• Impact of the 1-for-10 reverse stock split on July 7, 2025, potentially causing further stock price decline and decreased liquidity.
• Any failure to maintain effective internal control over financial reporting could harm the company.
• Limited trading market for common stock, making it difficult to liquidate investments.
• Lack of public company experience of the management team, potentially impacting compliance with U.S. securities laws.
• Being a smaller reporting company, which may make the stock less attractive to potential investors.
• Increased audit and legal costs associated with periodic reporting requirements, negatively affecting profitability.
• No intention to pay cash dividends, meaning stockholders will only receive a return through stock sales.
• Authorization to issue blank check preferred stock without stockholder approval, which could adversely impact common stockholders' rights or deter change of control.

Future Outlook

The company's future operations are dependent on the success of its ongoing development and commercialization efforts for drug candidates like bezisterim (for Parkinson's and Long COVID) and BIV201 (for liver cirrhosis and ascites), as well as its ability to secure additional financing. Management expects future funding to come from equity sales, loans, or strategic transactions. The company is currently finalizing the protocol design for a Phase 3 study of BIV201.

Management Comments

• Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.
• Management believes that the expectations reflected in the forward-looking statements are reasonable, but cannot guarantee future results, levels of activity, performance or achievements.
• The company believes that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID.
• BioVie believes that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID.
• The company believes that BIV201 (continuous infusion terlipressin) has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis.

Industry Context

BioVie operates in the highly competitive biopharmaceutical industry, characterized by rapid technological developments and significant R&D investment. The company is targeting large unmet medical needs in neurodegenerative diseases (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease (ascites). While there are no FDA-approved drugs specifically for ascites due to liver cirrhosis, other companies are developing therapies for severe complications of advanced liver cirrhosis. In AD and PD, major pharmaceutical companies like Biogen and Eli Lilly are also developing treatments, indicating intense competition. The company's focus on inflammation-driven insulin resistance as a mechanism for neurodegenerative diseases represents an emerging scientific consensus, potentially offering a novel approach.

Comparison to Industry Standards

• The company's Phase 3 AD trial was designed to be 80% powered with 125 patients in each arm, a standard for pivotal trials, but the unplanned exclusion of patients due to protocol deviations left it underpowered, falling short of industry expectations for robust data.
• The successful completion of the Phase 2 PD study, meeting safety, tolerability, and pharmacokinetics objectives, and showing preclinical indications of promotoric activity and levodopa enhancement, aligns with typical early-stage drug development milestones.
• The $13.1 million grant from the U.S. Department of Defense for the Long COVID program is a significant external validation and funding source, comparable to grants received by other biotech firms for addressing public health priorities.
• The company's pre-revenue status and substantial accumulated deficit are common for clinical-stage biopharmaceutical companies, but the 'going concern' warning indicates a higher level of financial distress compared to peers with more robust funding or clearer paths to commercialization.
• The ongoing securities class action and derivative lawsuits, stemming from clinical trial integrity issues, represent a significant deviation from good clinical practices and corporate governance standards, potentially impacting investor confidence and operational focus more severely than typical industry litigation.

Corporate Governance

Legal Proceedings

• On January 19, 2024, a shareholder class action complaint, Eric Olmstead v. BioVie Inc. et al., was filed in the U.S. District Court for the District of Nevada, alleging material misrepresentations and/or omissions related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable Alzheimer's Disease.
• A second, related putative securities class action, Way v. BioVie Inc. et al., was filed on February 22, 2024, asserting similar claims.
• These two actions were consolidated on April 15, 2024, under In re BioVie Inc. Securities Litigation, with an amended complaint filed on June 21, 2024, seeking unspecified monetary damages and costs.
• The defendants' motion to dismiss the amended complaint was denied on March 27, 2025, and the parties are now in the early stages of fact discovery.
• On December 30, 2024, a shareholder derivative lawsuit, Andrew Hulm, was filed, alleging breach of fiduciary duties, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control; this lawsuit was stayed on March 18, 2025.
• On April 28, 2025, a second shareholder derivative lawsuit, William Settel, was filed, alleging essentially the same claims as the Hulm action.
• The company believes these claims are without merit and intends to defend vigorously, but acknowledges the inherent uncertainties, significant resource expenditure, and potential for substantial damages or fines, with insurance coverage subject to a $2 million deductible.

Related Party Transactions

• The company acquired biopharmaceutical assets, including NE3107 (bezisterim), from NeurMedix, Inc., a privately held clinical-stage pharmaceutical company and a related party, in June 2021.
• On July 15, 2022, the company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (Acuitas), the company's largest stockholder, for the purchase of common stock and warrants.
• The warrants issued to Acuitas included 'ratchet adjustment' features, resulting in deemed dividends of $369,465 for FY2025 and $886,423 for FY2024 due to subsequent capital raises that reduced the exercise price.
• During FY2025, the company paid a Director $50,000 for consulting services, reflected as a component of selling, general and administrative expenses.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity offerings and the exercise of outstanding warrants and options, as well as potential dilution from milestone-based stock issuances related to acquired drug candidates.
• Shareholders are exposed to substantial financial risk, including the potential for complete loss of investment, due to the company's 'going concern' doubt, lack of revenue, and accumulated deficit.
• Shareholders are directly impacted by the volatility of the stock price and the ongoing securities class action litigation, which could lead to a decline in share value and make it difficult to liquidate investments.
• Employees and management are subject to the company's Clawback Policy for incentive-based compensation in the event of accounting restatements, and the Insider Trading Policy restricts their trading activities.
• Employees and management are also impacted by the ongoing litigation, which diverts management attention and resources.
• Creditors and lenders face increased risk due to the company's 'going concern' warning and reliance on future capital raises to fund operations.
• Patients and the medical community are impacted by the progress and outcomes of the company's clinical trials for neurological and liver diseases, particularly the setbacks in the Alzheimer's trial and the commencement of new Parkinson's and Long COVID studies.

Next Steps

• Continue enrolling patients or design a new Phase 3 study for bezisterim in Alzheimer's disease to achieve statistical significance, following the issues with the previous trial.
• Proceed with the new Phase 2b study of bezisterim as a potential first-line therapy for new onset Parkinson's disease, which commenced in April 2025.
• Continue the Phase 2 ADDRESS-LC study of bezisterim for neurological symptoms associated with Long COVID, which commenced in May 2025.
• Finalize the protocol design for the Phase 3 study of BIV201 for cirrhosis and ascites, focusing on a composite primary endpoint of complications and disease progression in patients who have recently recovered from AKI.
• Engage in the early stages of fact discovery for the consolidated securities class action lawsuit, following the court's denial of the motion to dismiss.
• Address the shareholder derivative lawsuits, which are currently stayed pending resolution of the securities class action.
• Seek additional financing through sales of equity, obtaining loans, or other strategic transactions to fund continuing operations.

Key Dates

Recommendation

The filing explicitly states 'These circumstances raise substantial doubt on the Company’s ability to continue as a going concern,' which is a critical red flag for any investor. This fundamental financial instability, coupled with the severe integrity issues and underpowering of the pivotal Alzheimer's Phase 3 trial, and the ongoing, costly securities class action and derivative lawsuits, presents an extremely high-risk profile. While the company has secured a significant DOD grant and initiated new trials, these future-oriented positives do not offset the immediate and profound financial and legal challenges. The risk of total capital loss is substantial, making a 'strong sell' recommendation appropriate for a seasoned investor.

Keywords

Biopharmaceutical, Neurodegenerative, Alzheimer's Disease, Parkinson's Disease, Long COVID, Liver Disease, Ascites, Bezisterim, NE3107, BIV201, Terlipressin, Clinical Trials, FDA, Orphan Drug, Fast Track, SEC Filing, 10-K, Biotech, Drug Development, Clinical Stage